Search results
Results From The WOW.Com Content Network
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [13]
A variety of stories feature on Saturday's front pages. The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to ...
AstraZeneca is advancing early stage trials of several cell therapies in different types of cancer including liver and prostate cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak ...
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion. Icosavax is developing a combination vaccine ...
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca , [ 33 ] [ 34 ] [ 35 ] using as a vector the modified ...
The detained individuals, all Chinese nationals, were associated with the marketing of oncology drugs in China, where AstraZeneca generates approximately 13% of its global revenue.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria [6] and Covishield, [7] is a viral vector vaccine [8] produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations.